Over the past decade, CAR-T cell therapy, a form of cancer immunotherapy, has shown significant promise, largely due to advances in gene delivery methods. Adeno-associated virus (AAV), particularly AAV6, is notable for its high affinity to immune cells, but its application is limited by the need for high viral loads of cell-penetrating peptides (CPPs) for effective T cell modification. A recent paper published in The Journal of Gene Medicine by Dr. Amine Kamen’s group at McGill University highlights the potential of cell-penetrating peptides (CPPs) in overcoming this limitation. TAT-HA2 and LAH4, two tested CPPs, have been shown to significantly enhance AAV6 transduction into T cells. These positively charged peptides increase transduction by concentrating viral particles on the cell surface. Notably, lower concentrations of these CPPs were effective in improving transducibility, while higher concentrations were found to cause cellular toxicity. Combining these peptides did not yield further improvement.
The research demonstrated that pre-incubating AAV6 with CPPs like TAT-HA2 and LAH4 led to a significant increase in transduction efficiency. TAT-HA2 assists in cell membrane translocation, and LAH4 binds to plasma membranes, both contributing to the improved release of AAV particles from endosomes. Microscopy analysis supported these findings, showing an increased uptake of AAV6-LAH4 complexes in T cells. The study posits that LAH4 might enhance transduction by stimulating nuclear trafficking or promoting cargo release, while TAT-HA2 is likely to aid in endosomal escape.
Interestingly, the study found that the large size of AAV6-LAH4 complexes, which might suggest the involvement of macropinocytosis, did not play a significant role in the transduction process. The increased transduction efficiency seems to be related to the ability of CPPs to deposit viral vectors near the cell membrane through electrostatic interactions. Importantly, the immune response to AAV vectors complexed with CPPs appeared unchanged, suggesting that CPPs do not intensify the host cell immune response and supporting their potential for safe use in gene therapies.
The study detailed above underscores the effectiveness of a 30-minute pre-incubation with cell-penetrating peptides (CPPs) in enhancing AAV6-mediated transgene delivery into T cells, which represents a significant stride in cellular immunotherapy. This method, focusing on CPPs like TAT-HA2 and LAH4, offers an efficient way to concentrate viral particles on the cell surface, thereby improving transduction without exacerbating the host cell immune response. It opens up new possibilities in developing novel cellular immunotherapies reliant on AAV6-mediated gene delivery.
Building upon this advancement, an alternative and potentially complementary approach is being explored to further optimize gene delivery. This involves engineering a modified AAV6 with enhanced infectivity. PackGene, leveraging its π-icosa capsid engineering platform, has identified several AAV6 capsid variants that exhibit a tenfold improvement in infecting human primary T cells. These promising developments are still undergoing further characterization to fully understand their potential and applicability in gene therapy. To discover more about this cutting-edge research and the ongoing progress in AAV6 capsid variant development, you are encouraged to visit PackGene’s website for detailed information and updates.
Check out our AAV capsid engineering service to expedite your gene therapy research
Reference:
Enhancement of adeno-associated virus serotype 6 transduction into T cells with cell-penetrating peptides. Moço, P.D., Dash, S., Kamen A. A., J Gene Med. 2023 Nov 13. https://doi.org/10.1002/jgm.3627
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
